Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Angelina V. Ciaccia"'
Autor:
Michael H. Davidson, Suresh Siddhanti, Angelina V. Ciaccia, Cheryl A. Keech, Pandurang M. Kulkarni, William Insull
Publikováno v:
Metabolism. 54:939-946
Raloxifene and low-dose simvastatin can each reduce low-density lipoprotein (LDL) cholesterol without affecting high-density lipoprotein (HDL) cholesterol and triglycerides. The objective of this double-blind, 12-week study is to determine whether ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a502efbe4b778503053850aabdd5a57b
https://doi.org/10.1016/j.metabol.2005.02.010
https://doi.org/10.1016/j.metabol.2005.02.010
Autor:
Angelina V. Ciaccia, Nelson B. Watts, Derek Elmerick, David Muram, Susan R. Johnson, Steven R. Goldstein
Publikováno v:
Menopause. 12:160-164
Determine the effect of raloxifene or estrogen, as compared with placebo, on the reporting of urinary incontinence in postmenopausal women participating in an osteoporosis prevention trial.The current analysis is based on adverse event data that were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::836b279f1e3893a1fde469a003cfc056
https://doi.org/10.1097/00042192-200512020-00010
https://doi.org/10.1097/00042192-200512020-00010
Autor:
Bruce Ettinger, Leo Plouffe, Elena Moscarelli, Deborah Grady, Steven R. Cummings, Somnath Sarkar, Angelina V. Ciaccia
Publikováno v:
Obstetrics & Gynecology. 104:837-844
Objective To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen. Methods The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cd064d05bdc77ab6e7308d15dab4813
https://doi.org/10.1097/01.aog.0000137349.79204.b8
https://doi.org/10.1097/01.aog.0000137349.79204.b8
Autor:
John L. Stock, Angelina V. Ciaccia, Edward G. Lufkin, Suresh Siddhanti, Pandurang M. Kulkarni, Somnath Sarkar, Leo Plouffe
Publikováno v:
Current Medical Research and Opinion. 20:351-357
Standard pharmacological antiresorptive therapy for the prevention and/or treatment of postmenopausal osteoporosis now consists of four categories of drugs: estrogens, a selective estrogen receptor modulator (SERM), bisphosponates, and calcitonin. Al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8f928dfc31961ad3d5196451e4dff9a
https://doi.org/10.1185/030079904125003071
https://doi.org/10.1185/030079904125003071
Publikováno v:
Journal of Biological Chemistry. 276:11199-11203
Human protein C is a natural anticoagulant factor, and a recombinant activated form of the molecule (rhAPC) is completing clinical evaluation for treatment of severe sepsis. Because of the pathophysiologic role of endothelial dysfunction in severe in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::731f21cad3095cd1784011a9d005560a
https://doi.org/10.1074/jbc.c100017200
https://doi.org/10.1074/jbc.c100017200
Publikováno v:
Human Reproduction Update. 6:212-224
Selective oestrogen receptor modulators (SERMs) are structurally diverse non-steroidal compounds that bind to oestrogen receptors and produce oestrogen agonist effects in some tissues and oestrogen antagonist effects in others. SERMs are being evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bacbc487b81591689856b801ed8945a9
https://doi.org/10.1093/humupd/6.3.212
https://doi.org/10.1093/humupd/6.3.212
Publikováno v:
Cleveland Clinic Journal of Medicine. 67:273-280
Selective estrogen receptor modulators (SERMs) are a new class of drugs that provide a new option for addressing the health challenges of postmenopausal women. This review discusses the proposed mechanism of action of SERMs and describes clinical fin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::490ba5377bf7770606503596d6a06791
https://doi.org/10.3949/ccjm.67.4.273
https://doi.org/10.3949/ccjm.67.4.273
Autor:
Angelina V. Ciaccia, Frank C. Church
Publikováno v:
Protein & Peptide Letters. 4:215-224
Abstract: Hemostasis is a critical element of the host defense system. The "balance" in hemostasis is achieved by the tight regulation of both procoagulant and anticoagulant proteins. The focus of this short review is on one particular anticoagulant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::afde49498e2ac5cf048af6201ec0e0d0
https://doi.org/10.2174/092986650404221017120326
https://doi.org/10.2174/092986650404221017120326
Publikováno v:
Journal of Biological Chemistry. 272:14074-14079
Heparin cofactor II (HCII) is presumed to be a physiological inhibitor of the serine proteinase thrombin. The reaction between HCII and thrombin is quite unique, because it involves an unusual HCII-reactive site loop sequence of Leu444-Ser445, requir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::243ab6a2d6bf633c17d1f1298fc3c012
https://doi.org/10.1074/jbc.272.22.14074
https://doi.org/10.1074/jbc.272.22.14074
Publikováno v:
Journal of Biological Chemistry. 272:888-893
A heparin cofactor II (HCII) mutant with an Arg substituted for Leu444 at the P1 position (L444R-rHCII) was previously found to have altered proteinase specificity (Derechin, V. M., Blinder, M. A., and Tollefsen, D. M. (1990) J. Biol. Chem. 265, 5623
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::277a5f26ed2cccf23dfdc46790b4667f
https://doi.org/10.1074/jbc.272.2.888
https://doi.org/10.1074/jbc.272.2.888